Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

Researchers from the Huntington's Disease Center, UCL Queen Square Institute of Neurology, and UK DRI at UCL have taken major ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...

With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this ...